Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (20612)
All Articles published online
|
Publishing Process of This Article
|
Jul 28, 2022 (publication date) through Feb 16, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 2022; 28(28): 3608-3619 [PMID: 36161043 DOI: 10.3748/wjg.v28.i28.3608] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 2022; 28(28): 3608-3619 [PMID: 36161043 DOI: 10.3748/wjg.v28.i28.3608] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i28/3608.htm |
| Number | Citing Articles |
| 1 |
Georges Jourdi, Jean-Sébastien Hulot, Pascale Gaussem. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?. Expert Opinion on Drug Metabolism & Toxicology 2024; 20(8): 749 doi: 10.1080/17425255.2024.2378888
|
| 2 |
Xinxu Zhou, Hui Duan, Qian Li, Qiong Wang, Xiaobin Sun. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis. Scandinavian Journal of Gastroenterology 2024; 59(7): 788 doi: 10.1080/00365521.2024.2349638
|
| 3 |
Marzio Frazzoni, Leonardo Frazzoni. Functional Diseases of the Esophagus. Updates in Surgery 2026; : 93 doi: 10.1007/978-3-031-90570-4_10
|
| 4 |
Mujtaba Alrayah, Rajab Alzahrani, Mohammed A Alghamdi, Kholoud M Alghamdi, Faisal F Almutairi, Anwar A Alghamdi, Raghad A Alzahrani, Taif A Bajaber, Tahani F Alanazi, Haya A Alnafisah. Assessment of the Current Knowledge and Practice of General Practitioners Towards Laryngopharyngeal Reflux in Saudi Arabia. Cureus 2023; doi: 10.7759/cureus.38043
|
| 5 |
M.A. Valdovinos Díaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.A. Arenas-Martínez. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México (English Edition) 2024; 89(1): 121 doi: 10.1016/j.rgmxen.2023.12.002
|
| 6 |
Dong Chan Joo, Gwang Ha Kim. Fexuprazan for the Prevention of Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer: A New Player in the Gastroprotection Landscape. Gut and Liver 2025; 19(5): 633 doi: 10.5009/gnl250399
|
| 7 |
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, Edoardo Vincenzo Savarino, Maria Cecilia Giron. Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Expert Opinion on Drug Metabolism & Toxicology 2025; 21(1): 53 doi: 10.1080/17425255.2024.2397433
|
| 8 |
M.A. Valdovinos-Díaz, A. Hani, C. Defilippi-Guerra, L. Fernando-Pineda, J.M. Remes-Troche, A. Riquelme, L.J. Abrahão-Junior, L. Aguilar-Paiz, C. Almonte-Nuñez, H. Burgos, C. Días, O. Gómez-Escudero, I. Hanna-Jairala, C. Olano, J.A. Olmos, A. Ortiz, G. Otoya, J.L. Tamayo-de la Cuesta, J. Suazo-Barahona, E. Vesco-Monteagudo, L.R. Valdovinos-García, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica para el manejo de la enfermedad por reflujo gastroesofágico. Revisión por expertos latinoamericanos. Revista de Gastroenterología de México 2025; 90(2): 288 doi: 10.1016/j.rgmx.2025.02.001
|
| 9 |
Min Jeong Je, Jeong Min Go, Shin Yeong Kim, Min-Gul Kim, Hankil Lee, Ha-Lim Jeon, Jae Hyun Kim. Prescription trends of gastric acid suppressants and association with potential adverse events in Korea: a real-world cross-sectional study. Therapeutic Advances in Gastroenterology 2025; 18 doi: 10.1177/17562848251356406
|
| 10 |
E. A. Ortenberg, M. V. Lyapina, E. F. Dorodnyeva. Competitive proton pump inhibitors - status and Prospects of use. Experimental and Clinical Gastroenterology 2023; (4): 86 doi: 10.31146/1682-8658-ecg-212-4-86-92
|
| 11 |
Jeremy A. Klein, Robert T. Kavitt. Esophageal Disorders. 2025; : 21 doi: 10.1007/978-3-032-08179-7_3
|
| 12 |
Jeremy Klein, Robert T. Kavitt. Gastroesophageal Reflux Disease. 2023; : 61 doi: 10.1007/978-3-031-48241-0_8
|
| 13 |
Yue Yao Wu, Hai Feng Jin. Advances in the Treatment of Gastric Artificial Ulcers Following Endoscopic Submucosal Dissection (ESD). Journal of Digestive Diseases 2025; 26(11-12): 460 doi: 10.1111/1751-2980.70023
|
| 14 |
Shanshan Wei, Zhihao Huang, Huizhen Xiong, Ji Wu, Dihua Mei, Jing Zhao, Wei Liu, Qingyun Liu, Yu Lin, Fang Liu, Xiang Peng, Honglei Chen. Efficacy and Safety of Keverprazan–Amoxicillin Dual Regimen in Initial Eradication of Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter 2026; 31(1) doi: 10.1111/hel.70100
|
| 15 |
Shupeng Zou, Mengling Ouyang, Qian Cheng, Xuan Shi, Minghui Sun. Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2024; 44(2): 171 doi: 10.1002/phar.2899
|
| 16 |
Yunna Lee, Yuju Kim, Soyeong Park, Geunhyung Yang, Yong Ju Ahn, Yong Sung Kim, Eunok Im. Fexuprazan mitigates NSAID-induced small intestinal injury by restoring intestinal barrier integrity in mice. Biomedicine & Pharmacotherapy 2025; 190: 118386 doi: 10.1016/j.biopha.2025.118386
|
| 17 |
M.A. Valdovinos-Díaz, A. Hani, C. Defilippi-Guerra, L. Fernando-Pineda, J.M. Remes-Troche, A. Riquelme, L.J. Abrahão-Junior, L. Aguilar-Paiz, C. Almonte-Nuñez, H. Burgos, C. Días, O. Gómez-Escudero, I. Hanna-Jairala, C. Olano, J.A. Olmos, A. Ortiz, G. Otoya, J.L. Tamayo-de la Cuesta, J. Suazo-Barahona, E. Vesco-Monteagudo, L.R. Valdovinos-García, J.S. Arenas-Martínez. Good clinical practice recommendations for the management of gastroesophageal reflux disease. A Latin American expert review. Revista de Gastroenterología de México (English Edition) 2025; 90(2): 288 doi: 10.1016/j.rgmxen.2025.02.001
|
| 18 |
Boram Cha, Ju Yup Lee. Recent Advances in the Diagnosis and Treatment of Gastroesophageal Reflux Disease. Keimyung Medical Journal 2025; 44(1): 1 doi: 10.46308/kmj.2025.00101
|
| 19 |
Sunghwan Kim, Joon Sung Kim. Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study. Journal of Korean Medical Science 2026; 41(2) doi: 10.3346/jkms.2026.41.e43
|
| 20 |
Hyun Lim, Ju Yup Lee, Yong Hwan Kwon, Hee Seok Moon, Jong Kyu Park, Ki Bae Kim, Sang Wook Kim, Young Hoon Youn, Sang Gyun Kim, Gwang Ha Kim, Ji Won Kim, Jae-Young Jang, Kye Sook Kwon, Joong Goo Kwon, Hyun-Soo Kim, Su Jin Hong, Kwang Jae Lee, Suck Chei Choi, Jeong Seop Moon, Nayoung Kim, Jong-Jae Park, Yirang Lim, Sung Hee Hong, Hwoon-Yong Jung. Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. Gut and Liver 2025; 19(4): 519 doi: 10.5009/gnl240390
|
| 21 |
ChaoRong Bian, Ping Shen, YunPeng Zang, Wen Liu, Peng Zhou. Vonoprazan Fumarate: A Promising Therapeutic Option for the Rapid Relief of Laryngopharyngeal Reflux Disease. Journal of Voice 2025; 39(4): 862 doi: 10.1016/j.jvoice.2024.12.031
|
| 22 |
Iqbal Taufiqqurrachman, Ari Fahrial Syam, Hasan Maulahela, Murdani Abdullah, Takashi Matsumoto, Muhammad Miftahussurur, Yoshio Yamaoka. Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens for Helicobacter pylori eradication: a systematic review and network meta-analysis. BMJ Open Gastroenterology 2026; 13(1): e002037 doi: 10.1136/bmjgast-2025-002037
|
| 23 |
Simon Blaine‐Sauer, Jonathan Bock, Serhat Bor, Jacqueline Allen, Derrick R. Randall, Sumeet Mittal, Thomas L. Carroll. Extraesophageal reflux: Clinical manifestations and tools for diagnosis and treatment. Annals of the New York Academy of Sciences 2025; 1547(1): 233 doi: 10.1111/nyas.15349
|
| 24 |
Piotr Kucharczyk, Karolina Anna Parzęcka, Michał Jakub Symulewicz, Weronika Zań, Kinga Szczepanik, Olaf Domaradzki, Bartłomiej Kusy, Mateusz Michalak, Marta Stolińska. Innovative therapeutic strategies in the treatment of gastroesophageal reflux disease (GERD): A review of progress and perspectives. Wiadomości Lekarskie 2024; 77(6): 1271 doi: 10.36740/WLek202406124
|
| 25 |
Thai Hau Koo, Ronnie Fass. A systematic review and meta-analysis of randomized controlled trials: the role of potassium-competitive acid blockers in endoscopy-negative reflux disease. Digestive and Liver Disease 2025; 57(9): 1752 doi: 10.1016/j.dld.2025.04.045
|
| 26 |
Xinwei Qiao, Peng Li. Potassium-competitive acid blockers and advances in the management of patients with acid-related diseases: a narrative review. Frontiers in Physiology 2025; 16 doi: 10.3389/fphys.2025.1655102
|
| 27 |
Yicong Bian, Jinjie Yuan, Sheng Ma, Jiang Nan, Zheming Gu, Hao Feng, Zhenwen Yu, Zhenteng Liu, Fang Xie, Yinghui Wang, Chengxin Liu, Hua Zhang, Liyan Miao.
Mass balance and metabolite profiles in humans of tegoprazan, a novel potassium-competitive acid blocker, using
14
C-radiolabelled techniques
. Expert Opinion on Drug Metabolism & Toxicology 2025; 21(7): 897 doi: 10.1080/17425255.2025.2505637
|
| 28 |
Sowmya Errabaka, Haritha Pasupulati, Satyanarayana SV Padi. PRAZANs or PCABs, Potassium Competitive Acid Blockers: A New Therapeutic Class in Acid-Related Diseases. International Journal of Health Sciences and Research 2026; : 109 doi: 10.52403/ijhsr.20260215
|
| 29 |
Ming Lu, Yi Cui, Nailin Li, Yan He, Ling Zhou, Jin Xiu, Pingsheng Hu. Pharmacological characterization of linaprazan glurate (X842), a novel potassium-competitive acid blocker, in vitro and in vivo. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1636523
|
| 30 |
阳 高. Advances in the Treatment of Gastroesophageal Reflux Disease. Advances in Clinical Medicine 2024; 14(05): 1790 doi: 10.12677/acm.2024.1451617
|
| 31 |
Wenlu Wang, Hafiza Sidra Yaseen, Xiaoji Li, Muhammad Zia Ahmad, Yaowu Chen, Guorong Li, Muhammad Naveed, Hafiz Muhammad Zubair, Jannat Bibi. Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB). European Journal of Clinical Pharmacology 2025; 81(8): 1103 doi: 10.1007/s00228-025-03850-6
|
| 32 |
Katarzyna Hossa, Ewa Małecka-Wojciesko. Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies. Pharmaceuticals 2025; 18(5): 699 doi: 10.3390/ph18050699
|
| 33 |
Jiten P. Kothadia, Colin W. Howden. Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease. Foregut: The Journal of the American Foregut Society 2024; 4(1): 7 doi: 10.1177/26345161231181357
|
| 34 |
岚 卿. Progress of Potassium-Competitive Acid Blocker Tegoprazan in the Treatment of Acid-Related Diseases. Advances in Clinical Medicine 2024; 14(08): 117 doi: 10.12677/acm.2024.1482189
|
| 35 |
Eunsol Yang, Inyoung Hwang, Sang Chun Ji, John Kim, SeungHwan Lee. Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers. CPT: Pharmacometrics & Systems Pharmacology 2024; 13(12): 2150 doi: 10.1002/psp4.13228
|
| 36 |
S. V. Tikhonov, E. N. Kareva, S. Yu. Serebrova, G. F. Vasilenko, M. K. Vasilyeva, S. A. Makhortova, N. V. Pavlova. New achievements of pharmacology for practical medicine in prevention and therapy of acid-dependent diseases. Meditsinskiy sovet = Medical Council 2023; (8): 33 doi: 10.21518/ms2023-133
|
| 37 |
Sergey M Kotelevets. Risks of anti-<i>Helicobacter</i> therapy and long-term therapy with antisecretory drugs. World Journal of Gastroenterology 2025; 31(4): 101933 doi: 10.3748/wjg.v31.i4.101933
|
| 38 |
M.A. Valdovinos-Diaz, M. Amieva-Balmori, R. Carmona-Sánchez, E. Coss-Adame, O. Gómez-Escudero, M. González-Martínez, F. Huerta-Iga, E. Morel-Cerda, J.M. Remes-Troche, J.L. Tamayo-de la Cuesta, G. Torres-Villalobos, L.R. Valdovinos-García, G. Vázquez-Elizondo, A.S. Villar-Chávez, J.S. Arenas-Martínez. Recomendaciones de buena práctica clínica en el diagnóstico y tratamiento de la enfermedad por reflujo gastroesofágico. Revisión por expertos de la Asociación Mexicana de Gastroenterología. Revista de Gastroenterología de México 2024; 89(1): 121 doi: 10.1016/j.rgmx.2023.12.002
|
| 39 |
Seo Yeon Kim, Jung-Ho Yoon, Da Hyun Jung, Ga Hee Kim, Chul Hoon Kim, Sang Kil Lee. Fexuprazan safeguards the esophagus from hydrochloric acid-induced damage by suppressing NLRP1/Caspase-1/GSDMD pyroptotic pathway. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1410904
|
| 40 |
Su Il Kim, Young Chan Lee, Wonjae Cha, Ah Ra Jung, Jeon Yeob Jang, Jeong-Seok Choi, Dong Kun Lee, Hwan Ho Lee, Min Su Kwon, Yoon Se Lee, Young-Gyu Eun. Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial. European Archives of Oto-Rhino-Laryngology 2024; 281(11): 5873 doi: 10.1007/s00405-024-08877-6
|
| 41 |
Chaoying Lu, Hongqun Qiao. Embryo‐Fetal Developmental Toxicity and Toxicokinetics Studies of YWS1903, a Novel Potassium‐Competitive Acid Blocker, in Pregnant Rats. Birth Defects Research 2025; 117(5) doi: 10.1002/bdr2.2481
|